Atherogenic LOX-1 signaling is controlled by SPPL2-mediated intramembrane proteolysis

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • Torben Mentrup - , Institute of Physiological Chemistry, TUD Dresden University of Technology, Kiel University (Author)
  • Kosta Theodorou - , Maastricht University (Author)
  • Florencia Cabrera-Cabrera - , TUD Dresden University of Technology, Kiel University (Author)
  • Andreas O. Helbig - , Kiel University (Author)
  • Kathrin Happ - , Kiel University (Author)
  • Marion Gijbels - , Maastricht University, Amsterdam University Medical Centers (UMC) (Author)
  • Ann Christine Gradtke - , TUD Dresden University of Technology, Kiel University (Author)
  • Björn Rabe - , Kiel University (Author)
  • Akio Fukumori - , German Center for Neurodegenerative Diseases (DZNE) (Author)
  • Harald Steiner - , German Center for Neurodegenerative Diseases (DZNE), Ludwig Maximilian University of Munich (Author)
  • Andreas Tholey - , Kiel University (Author)
  • Regina Fluhrer - , German Center for Neurodegenerative Diseases (DZNE), Ludwig Maximilian University of Munich (Author)
  • Marjo Donners - , Maastricht University (Author)
  • Bernd Schröder - , Institute of Physiological Chemistry, TUD Dresden University of Technology, Kiel University (Author)

Abstract

The lectin-like oxidized LDL receptor 1 (LOX-1) is a key player in the development of atherosclerosis. LOX-1 promotes endothelial activation and dysfunction by mediating uptake of oxidized LDL and inducing pro-atherogenic signaling. However, little is known about modulators of LOX-1-mediated responses. Here, we show that the function of LOX-1 is controlled proteolytically. Ectodomain shedding by the metalloprotease ADAM10 and lysosomal degradation generate membrane-bound N-terminal fragments (NTFs), which we identified as novel substrates of the intramembrane proteases signal peptide peptidase-like 2a and b (SPPL2a/b). SPPL2a/b control cellular LOX-1 NTF levels which, following self-association via their transmembrane domain, can activate MAP kinases in a ligand-independent manner. This leads to an up-regulation of several pro-atherogenic and pro-fibrotic targets including ICAM-1 and the connective tissue growth factor CTGF. Consequently, SPPL2a/b-deficient mice, which accumulate LOX-1 NTFs, develop larger and more advanced atherosclerotic plaques than controls. This identifies intramembrane proteolysis by SPPL2a/b as a novel atheroprotective mechanism via negative regulation of LOX-1 signaling.

Details

Original languageEnglish
Pages (from-to)807-830
Number of pages24
JournalJournal of Experimental Medicine
Volume216
Issue number4
Publication statusPublished - 1 Apr 2019
Peer-reviewedYes

External IDs

PubMed 30819724

Keywords

ASJC Scopus subject areas